Sensitivity of secondary acute myeloid leukemia relapsing after allogeneic bone marrow transplantation to immunotherapy with interferon-α2b

S. Singhal*, R. Powles, J. Treleaven, J. Mehta

*Corresponding author for this work

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

A patient with acute myeloid leukemia secondary to therapy of choriocarcinoma underwent T cell non-depleted allogeneic bone marrow transplantation from an unrelated donor in first untreated relapse, Persistent/relapsed leukemia 4 months after transplantation did not respond to cessation of cyclosporine. Due to logistic difficulties in obtaining donor leukocytes, she was treated with interleukin-2 and interferon-α2b. Although the interleukin could be administered for a short period only, the interferon was continued for 4 months. Interferon was stopped when limited chronic graft-versus-host disease developed, but was followed by extramedullary and extra marrow relapse. Reinstitution of interferon resulted in the development of sclero-derma-like extensive chronic GVHD and remission. Interferon was given for 5 months. GVHD improved slowly with treatment, but scleroderma-like changes still persist. The patient is alive with no evidence of disease and a Karnofsky score of 90% 41 months after relapse and 26 months after stopping cyclosporine. We conclude that cytokines alone may occasionally result in a durable response of acute leukemia relapsing after allografting, and should be considered in patients with a low tumor burden if it is difficult to obtain donor cells.

Original languageEnglish (US)
Pages (from-to)1151-1153
Number of pages3
JournalBone Marrow Transplantation
Volume19
Issue number11
DOIs
StatePublished - Jun 1 1997

Keywords

  • Acute myeloid leukemia
  • Graft-versus-host disease
  • Graft-versus-leukemia
  • Immunotherapy
  • Interferon
  • Interleukin-2

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Sensitivity of secondary acute myeloid leukemia relapsing after allogeneic bone marrow transplantation to immunotherapy with interferon-α2b'. Together they form a unique fingerprint.

Cite this